Danaher Corporation research snapshot
DHR AI stock analysis currently reads Danaher Corporation as a high-quality life sciences, biotechnology, and diagnostics platform supported by the Danaher Business System, recurring consumables, regulated workflows, and disciplined capital deployment. At the August 2, 2026 data cutoff, DHR closed near $194.98 on July 31, 2026 with a verified market capitalization near $137.1 billion. The second quarter beat expectations with 5.5% revenue growth, 8.0% adjusted EPS growth, and a raised full year 2026 adjusted EPS guidance range of $8.45 to $8.60. The Masimo acquisition closed on June 10, 2026, earlier than planned, which lifts Diagnostics scale but also lifts total debt to roughly $27.9 billion. This page uses scenario ranges and source-backed checks, not a certain price prediction, and is for informational use only.
Current price
$194.98
Market cap
$137.1 billion
AI score
74 / 100
Rating
High-quality life sciences and diagnostics platform with improving core growth and a now-completed Masimo acquisition
Trend status
Constructive intermediate trend, with price holding above the 50-day and 100-day moving averages while still testing the 200-day area
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Danaher sells mission-critical biotechnology, life sciences, and diagnostics tools into regulated research, manufacturing, and clinical workflows with recurring consumables and service demand. | High |
| Moat | Moat comes from installed instruments, consumables pull-through, workflow switching costs, regulatory know-how, scale, proprietary technology, and the Danaher Business System operating model. | High |
| Management | Management closed the Masimo acquisition ahead of schedule and raised FY2026 guidance after a strong second quarter, but integration execution and the larger balance sheet now carry more weight. | Medium-high |
| Financial trend | Q2 2026 sales rose 5.5% to $6.3 billion with 3.0% core growth (4.5% ex respiratory). Adjusted diluted EPS rose 8.0% to $1.94, and FY2026 adjusted EPS guidance was raised to $8.45 to $8.60. | High |
| Valuation | At $194.98, DHR traded near 22.9x the $8.525 midpoint of 2026 adjusted EPS guidance, 2.6x book value, about 25.1x free cash flow per share, and 5.5x sales. | Medium-high |
| Technical trend | Price is above the 50-day moving average near $187.68 and the 100-day near $185.89 but still below the 200-day near $203.71, so the long-term trend is a test rather than a confirmed breakout. | Medium |
| Risk level | Key risks include slower bioprocessing revenue conversion, Diagnostics respiratory normalization, Masimo integration and its debt, StatLab integration, China policy headwinds, and multiple compression. | Medium-high |
| AI confidence | High for descriptive facts and audited math. Lower for price outcomes because the equity is sensitive to growth recovery, integration results, and terminal multiple assumptions. | High data confidence |
| Investment certainty | Medium certainty. DHR is a quality business, but the page gives a research framework and scenario ranges, not a buy or sell instruction. | Medium |
DHR AI stock forecast
The DHR AI stock forecast uses scenario math around the $194.98 quote and the $8.525 midpoint of Danaher updated 2026 adjusted diluted EPS guidance. The audited three-year framework produced a bearish area near $128, a base area near $217, and a bullish area near $287 before dividends. The range is wide because Danaher combines high business quality with a maturing life sciences recovery, Masimo integration, and higher leverage.
$275 to $300
More likely if bioprocessing orders convert into high-single-digit revenue growth, Life Sciences momentum continues, Diagnostics ex-respiratory growth stays mid-single digit, Masimo integrates cleanly with announced synergies, and the market values DHR near 26x forward adjusted EPS.
$205 to $230
More likely if adjusted EPS compounds around 5% a year, FY2026 guidance is met, free cash flow conversion stays high, respiratory testing normalizes as guided, and DHR trades near 22x forward adjusted EPS.
$120 to $145
More likely if bioprocessing revenue disappoints, Diagnostics respiratory revenue declines faster than guided, Masimo integration adds debt or distraction, tariff or China policy headwinds grow, and investors compress DHR toward a mid-teens earnings multiple.
DHR AI technical analysis
DHR AI technical analysis is constructive but not clean as of the August 2, 2026 data cutoff. Price closed near $194.98, above the 50-day and 100-day moving averages, but remained below the 200-day moving average near $203.71, so the recovery setup is intact while the long-term trend is still being tested.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $194.98 | Danaher investor relations and StockAnalysis both showed a $194.98 close on July 31, 2026, with a $137.1 billion market cap. |
| Near support | $185.9 to $187.7 | The 100-day moving average near $185.89 and the 50-day near $187.68 form a stacked support band from Barchart data. |
| Deeper support | $175 to $180 | Below the moving average band, the $175 to $180 zone is the next structural support before the 52-week low of $160.93. |
| Near resistance | $196 to $204 | The 5-day moving average near $196.64 and the 200-day moving average near $203.71 define the first resistance band. |
| Long-term resistance | $225 to $243 | This zone covers prior rebound supply and the 52-week high of $242.80 reported by Danaher investor relations. |
| Moving averages | 50-day near $187.68, 100-day near $185.89, 200-day near $203.71 | Barchart and StockAnalysis both show the same 200-day area near $203.71, and price is below it after holding above the shorter averages. |
| Momentum | RSI roughly 52 | StockAnalysis and Barchart both show a 14-day RSI near 52, a neutral reading with no overbought or oversold extreme. |
| Volume | Average volume near 6.5 million shares | StockAnalysis showed about 6.55 million and Barchart about 6.67 million shares on the 20-day average. |
| Volatility | $160.93 to $242.80 52-week range | Barchart showed a 14-day average true range near $7.36, and the wide 52-week range shows how demand, earnings, acquisition news, and rates can reset the stock. |
| Invalidation | Close below $185.9, then $180 | A decisive close below the 100-day area near $185.89 would weaken the recovery setup. A break below $180 would imply a failed intermediate trend. |
DHR AI trading strategy
The DHR AI trading strategy is a rules-based framework for monitoring a life sciences quality stock after a long reset. It is not personal advice and should be paired with live chart data, filings, position sizing, and defined invalidation levels.
Watch for DHR to hold above the $185.9 to $187.7 support band and reclaim the $196 to $204 resistance zone on volume near or above recent averages. Confirmation improves if Q3 results show core growth near the 2% to 3% guidance band with no margin slippage.
A close below $185.9, or a failed breakout after weaker core growth guidance, should invalidate the near-term trend setup.
If DHR pulls back toward the $187 to $188 area without new balance sheet, guidance, or demand damage, compare price action with FY2026 adjusted EPS guidance, free cash flow conversion, respiratory revenue, Masimo and StatLab integration, and tariff effects.
Do not average down without a maximum loss rule because healthcare tools stocks can gap lower when end-market demand, integration confidence, or leverage changes.
Track core revenue growth by segment, bioprocessing order trends, Life Sciences instruments demand, Diagnostics respiratory and ex-respiratory revenue, Cepheid trends, Masimo contribution and integration, StatLab closing, China policy impact, adjusted operating margin, free cash flow, total debt, and net interest expense.
Reduce confidence if EPS growth depends mainly on cost actions or multiple expansion while organic growth, free cash flow conversion, and leverage trends worsen.
Investment research summary
Danaher helps biopharma, research, industrial, and clinical customers develop therapies, run labs, manufacture biologics, and diagnose disease. Customers pay because these workflows are regulated, time-sensitive, and costly to rebuild internally.
The moat is built from installed systems, consumables, workflow know-how, service networks, regulatory familiarity, scale, technology, and operating discipline. It weakens if customers delay instruments, competitors lower consumables pricing, or new methods reduce the need for current workflows.
The thesis fails if bioprocessing orders do not convert into revenue, Diagnostics loses respiratory revenue faster than guided, Masimo or StatLab integration distracts management or adds debt, China and tariff headwinds persist, or acquisition goodwill and intangibles prove too optimistic.
Rainer Blair and the Danaher Business System provide continuity. Investors should judge management by organic growth recovery, Masimo and StatLab integration, acquisition discipline, cash conversion, and willingness to protect long-term innovation over short-term EPS optics.
Danaher sits inside long-duration demand for biologic drugs, diagnostics, clinical testing, lab automation, and life sciences productivity. The counterweight is that customer budget cycles and post-pandemic inventory normalization still govern the pace of growth.
At roughly 22.9x 2026 adjusted EPS guidance, the market prices DHR as a quality recovery story with a growing diagnostics franchise rather than a distressed healthcare tools stock. Margin of safety depends on real core growth, free cash flow durability, and disciplined use of a larger balance sheet.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| DHR price | $194.98 close on July 31, 2026 | Danaher investor relations stock quote and StockAnalysis | August 2, 2026 |
| Market capitalization | $137.1 billion, verified as $194.98 x 702.99 million shares with 0.00% variance | financial_rigor.py market cap verification | August 2, 2026 |
| Shares outstanding | 702.99 million shares per StockAnalysis, down 1.87% year over year | StockAnalysis share statistics | August 2, 2026 |
| Q2 2026 results | $6,265 million sales, +5.5% YoY; $870 million net earnings; $1.23 GAAP diluted EPS; $1.94 adjusted diluted EPS, +8.0% YoY | Danaher Q2 2026 results release | August 2, 2026 |
| Q2 2026 core growth | 3.0% non-GAAP core revenue growth, or 4.5% excluding respiratory testing; Biotechnology +2.5%, Life Sciences +5.5%, Diagnostics +2.0% | Danaher Q2 2026 results release | August 2, 2026 |
| H1 2026 results | $12,216 million sales, +4.5% YoY; $1,899 million net earnings; $2.68 GAAP diluted EPS; $4.00 adjusted diluted EPS | Danaher Q2 2026 results release | August 2, 2026 |
| Q2 2026 cash flow | Operating cash flow $1,534 million and non-GAAP free cash flow $1,265 million, up roughly 14.5% and 15.5% YoY | Danaher Q2 2026 results release | August 2, 2026 |
| FY2026 guidance | Adjusted diluted EPS raised to $8.45 to $8.60 (midpoint $8.525) from $8.35 to $8.55; full year core revenue growth of 3.0% to 4.0%; Q3 core growth of 2.0% to 3.0% | Danaher Q2 2026 results release | August 2, 2026 |
| FY2025 results | $24.6 billion revenue, +3.0% YoY; $3.6 billion net earnings; $5.03 GAAP diluted EPS; $7.80 adjusted diluted EPS, +4.5% YoY; $5.3 billion non-GAAP free cash flow | Danaher FY2025 results release | August 2, 2026 |
| Masimo acquisition | Completed June 10, 2026 for $180 per share cash, or roughly $9.9 billion enterprise value; expected to be a standalone Diagnostics operating company | Danaher Masimo acquisition releases | August 2, 2026 |
| Cash and debt | StockAnalysis listed $4.35 billion cash and $27.86 billion total debt, with net cash of negative $23.51 billion, reflecting debt raised for Masimo | StockAnalysis statistics | August 2, 2026 |
| TTM financials | Trailing twelve-month revenue $25.11 billion, net income $4.00 billion, EPS $5.63, operating cash flow $6.64 billion, free cash flow $5.47 billion | StockAnalysis statistics | August 2, 2026 |
| Valuation snapshot | Trailing PE 34.73, forward PE 22.03, PS 5.46, PB 2.61, P/FCF 25.08, EV/EBITDA 20.97, dividend yield 0.82% | StockAnalysis statistics | August 2, 2026 |
| Technical snapshot | RSI 52.26, 50-day MA $187.68, 100-day MA $185.89, 200-day MA $203.71; 20-day average volume about 6.5 million shares | Barchart technical analysis and StockAnalysis statistics | August 2, 2026 |
| Three-scenario valuation | financial_rigor.py output: bullish $287.0, base $217.1, bearish $128.4 using $8.525 EPS, 9% / 5% / -2% growth and 26x / 22x / 16x PE | financial_rigor.py three-scenario calculation | August 2, 2026 |
This DHR AI stock analysis is an informational research tool only and is not investment advice, financial planning, or a recommendation to buy, sell, or hold Danaher Corporation. Forecast ranges are scenarios based on available data as of August 2, 2026, and can be wrong if earnings, demand, rates, acquisition integration, regulation, or market multiples change.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
